GlassScriptPhysician profile
Dustin Wayne Bogan
NPI 1790220341
$3,151.41
in general payments reported to CMS, 2019-2025
19 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2022: $546 · 2023: $632 · 2024: $971 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $10.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.86 |
| Education | $10.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $1,211.48 | 2021-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $654.79 | 2022-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $351.87 | 2023-2025 | Qelbree, Qelbree |
| Alk-Abello, INC | $232.45 | 2024-2025 | Grastek, Odactra, Ragwitek |
| Kaleo, INC. | $142.45 | 2021-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $113.16 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $96.66 | 2025 | Jornay Pm |
| Sobi, INC | $59.74 | 2021 | |
| Cranial Technologies, INC | $53.81 | 2022-2023 | Doc Band |
| Pfizer INC. | $39.14 | 2021-2025 | |
| Verrica Pharmaceuticals INC. | $32.68 | 2023 | Ycanth |
| Ultragenyx Pharmaceutical INC. | $32.33 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $27.51 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $25.00 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $19.27 | 2023 | Vaxneuvance, Proquad, Vaxelis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $15.80 | 2024 | Immunocap |
| Genentech USA, INC. | $15.67 | 2021 | |
| Seqirus USA INC | $13.91 | 2022 | |
| Neos Therapeutics, LP | $13.69 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Bogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.